MiNK Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	0	0	0	0	0.69
Gross Profit	0	0	0	0	0.69
Selling, General & Admin	7.43	7.83	4.64	1.29	3.83
Research & Development	15.49	23.12	13.97	9.51	19.65
Other Operating Expenses	0	0	9.75	3	-0.55
Operating Expenses	22.92	30.95	28.36	13.8	22.93
Operating Income	-22.92	-30.95	-28.36	-13.8	-22.24
Interest Expense / Income	0	0	2.43	2.44	1.56
Other Expense / Income	-0.46	-2.96	-0.58	-	-
Pretax Income	-22.46	-27.99	-30.21	-16.24	-23.8
Net Income	-22.46	-27.99	-30.21	-16.24	-23.8
Shares Outstanding (Basic)	34	34	26	24	9
Shares Outstanding (Diluted)	34	34	26	24	9
Shares Change	2.04%	29.38%	7.95%	178.87%	-
EPS (Basic)	-0.65	-0.83	-1.16	-0.67	-2.75
EPS (Diluted)	-0.65	-0.83	-1.16	-0.67	-2.75
Free Cash Flow	-15.84	-19.12	-13.08	-8.43	-15.37
Free Cash Flow Per Share	-0.46	-0.57	-0.50	-0.35	-1.78
Gross Margin	-	-	-	-	100.00%
Operating Margin	-	-	-	-	-3225.13%
Profit Margin	-	-	-	-	-3451.46%
Free Cash Flow Margin	-	-	-	-	-2228.86%
EBITDA	-22.25	-27.87	-27.7	-13.74	-22.2
EBITDA Margin	-	-	-	-	-3219.79%
Depreciation & Amortization	0.2	0.12	0.08	0.06	0.04
EBIT	-22.46	-27.99	-27.78	-13.8	-22.24
EBIT Margin	-	-	-	-	-3225.13%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).